Evidence map›Paper›PMID 25049245›Full record

ArticleAntimicrobial agents and chemotherapy2014

Experimental therapy with azoles against Candida guilliermondii.

Marta Sanchis, Francisco Javier Pastor, Javier Capilla, Deanna A Sutton, Annette W Fothergill, Josep Guarro

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Marta SanchisUnitat de Microbiologia and Unitat d'Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain.
Francisco Javier PastorUnitat de Microbiologia and Unitat d'Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain.
Javier CapillaUnitat de Microbiologia and Unitat d'Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain.
Deanna A SuttonFungus Testing Laboratory, University of Texas Health Science Center, San Antonio, Texas, USA.
Annette W FothergillFungus Testing Laboratory, University of Texas Health Science Center, San Antonio, Texas, USA.
Josep GuarroUnitat de Microbiologia and Unitat d'Anatomia Patològica, Facultat de Medicina i Ciències de la Salut, IISPV, Universitat Rovira i Virgili, Reus, Tarragona, Spain josep.guarro@urv.cat.
Institut d'Investigació Sanitària Pere Virgili · ESThe University of Texas Health Science Center at San Antonio · USUniversidad Rovira i Virgili · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the in vitro killing activity of voriconazole (VRC) and posaconazole (PSC) against two clinical isolates of Candida guilliermondii. The two drugs showed fungistatic activity against both isolates and were effective in reducing kidney fungal burden in a neutropenic murine model of disseminated candidiasis in infected mice. PSC was significantly more effective than VRC against one of the strains. The serum levels of PSC and VRC were above the corresponding MICs for these isolates.

Indexed as

Antifungal AgentsAzolesCandidaMicrobial Sensitivity TestsTriazolesVoriconazoleAntifungal AgentsAzolesposaconazoleTriazolesVoriconazole

Identifiers

PMID25049245
PMCPMC4187986
OpenAlexW2140034856

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.